Abstract
Invasive cervical cancer is a common problem worldwide and while rates of squamous cell carcinoma of the cervix (SCC) have been declining with the implementation of community screening programs, adenocarcinoma of the cervix (ADC) has not shown a similar response to screening. At this time, the two entities are tested for and treated with the same clinical algorithms, namely gynecologic cytology and molecular testing for HPV DNA. However, ADC arises more proximally within the cervical canal and frequently occurs below the superficial mucosal lining, precluding it from being easily diagnosed with cytologic examination. Furthermore, ADC has a more aggressive course than SCC and is significantly less responsive to radiotherapy. These factors combine to produce a lesion that is diagnosed at a higher stage and has an overall poorer prognosis than SCC. While both lesions have pathogenic origins with the high-risk species of Human papilloma viruses (HPV), the high association of ADC with HPV 18, a virus with a higher genome integration rate, suggests that the transformation pathway of ADC differs from SCC. Modern methods of molecular analysis can produce gene expression profiles of various cell types and preliminary studies have shown that SCC and ADC do, indeed, produce a distinct genetic signature and can be reproducibly segregated. This technology has promise for clinical applicability in the diagnosis, the prognostic stratification, formation of a treatment care plan and post-therapeutic monitoring of ADC.
Keywords: Adenocarcinoma of the cervix, microarray technology, diagnosis, prognosis, treatment, post-therapeutic monitoring, cervical cancer, screening, molecular testing, squamous cell carcinoma of the cervix
Current Pharmaceutical Design
Title:Clinical Applicability of Microarray Technology in the Diagnosis, Prognostic Stratification, Treatment and Clinical Surveillance of Cervical Adenocarcinoma
Volume: 19 Issue: 8
Author(s): Julie Chepovetsky, Tamara Kalir and Elisabete Weiderpass
Affiliation:
Keywords: Adenocarcinoma of the cervix, microarray technology, diagnosis, prognosis, treatment, post-therapeutic monitoring, cervical cancer, screening, molecular testing, squamous cell carcinoma of the cervix
Abstract: Invasive cervical cancer is a common problem worldwide and while rates of squamous cell carcinoma of the cervix (SCC) have been declining with the implementation of community screening programs, adenocarcinoma of the cervix (ADC) has not shown a similar response to screening. At this time, the two entities are tested for and treated with the same clinical algorithms, namely gynecologic cytology and molecular testing for HPV DNA. However, ADC arises more proximally within the cervical canal and frequently occurs below the superficial mucosal lining, precluding it from being easily diagnosed with cytologic examination. Furthermore, ADC has a more aggressive course than SCC and is significantly less responsive to radiotherapy. These factors combine to produce a lesion that is diagnosed at a higher stage and has an overall poorer prognosis than SCC. While both lesions have pathogenic origins with the high-risk species of Human papilloma viruses (HPV), the high association of ADC with HPV 18, a virus with a higher genome integration rate, suggests that the transformation pathway of ADC differs from SCC. Modern methods of molecular analysis can produce gene expression profiles of various cell types and preliminary studies have shown that SCC and ADC do, indeed, produce a distinct genetic signature and can be reproducibly segregated. This technology has promise for clinical applicability in the diagnosis, the prognostic stratification, formation of a treatment care plan and post-therapeutic monitoring of ADC.
Export Options
About this article
Cite this article as:
Chepovetsky Julie, Kalir Tamara and Weiderpass Elisabete, Clinical Applicability of Microarray Technology in the Diagnosis, Prognostic Stratification, Treatment and Clinical Surveillance of Cervical Adenocarcinoma, Current Pharmaceutical Design 2013; 19 (8) . https://dx.doi.org/10.2174/1381612811319080009
DOI https://dx.doi.org/10.2174/1381612811319080009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations
Current Drug Metabolism Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics Diaryl Urea: A Privileged Structure in Anticancer Agents
Current Medicinal Chemistry Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Topoisomerase I-DNA Complex Stability Induced by Camptothecins and Its Role in Drug Activity&#
Current Medicinal Chemistry - Anti-Cancer Agents GnRH Agonists and Antagonists in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents A Novel Quinazoline-4-one Derivatives as a Promising Cytokine Inhibitors: Synthesis, Molecular Docking, and Structure-activity Relationship
Current Pharmaceutical Biotechnology Crocetin as an Active Secondary Metabolite of Saffron Stigma and Anticancer Effects
Current Cancer Therapy Reviews Cry1A Proteins are Cytotoxic to HeLa but not to SiHa Cervical Cancer Cells
Current Pharmaceutical Biotechnology Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Nanotechnology in Dentistry: Drug Delivery Systems for the Control of Biofilm-Dependent Oral Diseases
Current Drug Delivery Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry EGFR Inhibitors and Radiation in HNSCC
Current Cancer Therapy Reviews Synthesis of Aza-BODIPY Boron Difluoride PDT Agents to Promote Apoptosis in HeLa Cells
Letters in Organic Chemistry Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis
Current Cancer Therapy Reviews Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Transition Metal Based Anticancer Drugs
Current Topics in Medicinal Chemistry Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets